Alan Mintz
Vascular Surgery · Thousand Oaks, CANPI 1396786497
Payments from drug & device makers
Across 67 payments — averaging $41.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Silk Road Medical, Inc.$983
- Smith+Nephew$276
- Medline Industries LP$156
- Biotissue Holdings Inc.$147
- Osiris Therapeutics Inc.$123
- Medtronic$120
- plus $946 from 19 others
What the payments were for
- Travel & lodging$63523%
- Food & beverage$2,11877%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Silk Road Medical, Inc. | 10 | $983 |
| Smith+Nephew | 4 | $276 |
| Medline Industries LP | 10 | $156 |
| Biotissue Holdings Inc. | 2 | $147 |
| Osiris Therapeutics Inc. | 1 | $123 |
| Medtronic | 4 | $120 |
| KCI USA, Inc. | 1 | $100 |
| Getinge USA Sales, LLC | 4 | $91 |
| Tactile Systems Technology Inc | 6 | $87 |
| Organogenesis Inc. | 4 | $87 |
| Misonix Inc | 2 | $81 |
| Baxter Healthcare | 2 | $70 |
| Cardiovascular Systems Inc. | 2 | $57 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 1 | $55 |
| Bard Peripheral Vascular, Inc. | 1 | $55 |
| Lemaitre Vascular, Inc. | 3 | $55 |
| Acell, Inc. | 1 | $38 |
| Johnson & Johnson | 2 | $35 |
| Abbott | 1 | $30 |
| Cook Medical LLC | 1 | $27 |
| Angiodynamics, Inc. | 1 | $22 |
| GE HealthCare | 1 | $20 |
| Endologix LLC | 1 | $20 |
| Pfizer | 1 | $15 |
| Amniox Medical, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,752 in reported general payments places this provider in the 40th percentile of 519 vascular surgery providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 23 | $9,813 |
| Lidocaine | 13 | $161 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $276 | $9,81323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 519 vascular surgery providers in California.
Other vascular surgery in Thousand Oaks
- Venita ChandraPalo Alto$947K
- Leigh Ann ObanionFresno$932K
- Sukgu HanLos Angeles$765K
- Mahmoud Malasla Jolla$508K
- Son DuongFountain Valley$503K
- Leo FongClovis$496K
- Jason LeePalo Alto$403K
- Bernardo Curi MendesLos Angeles$376K
- Trevor DerderianRancho Mirage$359K
- Karthikeshwar KasirajanPalo Alto$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.